Product Overview: Trizapatide Xeno Labs
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist peptide developed for metabolic research applications. This synthetic peptide represents a breakthrough in incretin-based therapeutic research, combining the actions of both GIP and GLP-1 pathways to investigate complex glucose homeostasis mechanisms. Manufactured by Xeno Labs, this research-grade compound enables scientists at Stroid UK Shop to examine advanced metabolic modulation pathways in controlled experimental settings.
Laboratory Applications
Research teams investigating tirzepatide focus on its dual receptor mechanism, which activates both GIP and GLP-1 receptors simultaneously. Studies examine how this compound modulates pancreatic beta-cell function, insulin secretion patterns, and glucagon release in experimental models. Scientists particularly analyse its effects on glucose-dependent insulin stimulation, gastric emptying rates, and food intake regulation in metabolic research protocols. The compound’s unique dual-agonist properties make it valuable for metabolic pathway studies exploring incretin hormone interactions. Researchers also investigate its potential applications in diabetes research models, examining how dual GIP/GLP-1 activation affects glucose tolerance and insulin sensitivity. Advanced studies explore the compound’s effects on body weight regulation mechanisms and energy expenditure pathways. Teams studying selective receptor modulators often compare tirzepatide’s dual-target approach with single-pathway compounds. The peptide’s stability profile and dosing characteristics make it suitable for both acute and chronic experimental protocols in metabolic research laboratories studying peptide therapeutics.
Technical Specifications
| Chemical Name | Tirzepatide |
|---|---|
| Molecular Class | Dual GIP/GLP-1 Receptor Agonist Peptide |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4813.54 g/mol |
| Manufacturer | Xeno Labs |
| Form | Lyophilised powder |
| Storage | -20°C, dry conditions |
Research Compliance
This tirzepatide preparation from Xeno Labs is manufactured exclusively for in-vitro research and laboratory analysis. The compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must maintain appropriate laboratory protocols, storage conditions, and safety measures when handling this material. All studies should comply with institutional guidelines for peptide research and maintain detailed experimental documentation for regulatory compliance.
